Effect of Shilajatu Darvi Yoga on plasma expression of Apolipoprotein A-IV (ApoA-IV) and Thioredoxin interacting protein (TXNIP) in the patients of Madhumeha (Type 2 Diabetes Mellitus).
Phase 3
- Conditions
- Health Condition 1: E119- Type 2 diabetes mellitus without complications
- Registration Number
- CTRI/2024/01/061750
- Lead Sponsor
- Prof Dr Tanuja Nesari
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Fasting plasma glucose: = 126 mg/dL – 200 mg/dL
2.2-h plasma glucose: >200 mg/dL – 350 mg/dL
3.Symptoms of diabetes plus random blood glucose = 200 mg/dl.
4.HbA1C: 6.5% - 10%
5.Patients in between 40 and 60 years of either sex.
Exclusion Criteria
1.Patients of type-1 diabetes mellitus.
2.Cases with severe diabetic complications such as cardiac disease, nephropathy, and foot ulcer.
3.Patients with chronic diseases such as Tuberculosis, Bronchial asthma, Chronic renal
failure, HIV, and Hepatitis.
4.Patient below 40 years and above 60 years.
5.Patients taking medication that may cause rapid glucose rise e.g. steroids, antipsychotics.
6.Patients with acute pancreatic damage, including pancreatic surgery.
7.Pregnancy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Modulatory effect of Shilajatu Darvi Yoga on the plasma levels of protein apoA-IV & TXNIP in type 2 diabetic patients will be evaluated.Timepoint: Baseline. 60th and 90th day
- Secondary Outcome Measures
Name Time Method Effect of Shilajatu Darvi Yoga on Blood sugar level (Fasting & PP), HbA1c, CBC, LFT, KFT, & Lipid profile in patients of Type 2 Diabetes Mellitus will be determined.Timepoint: Fasting & PP blood sugar levels at Baseline, 30th, 60th & 90th day. <br/ ><br>HbA1c, CBC, LFT, KFT & Lipid profile at Baseline & 90th day.